Haleon plc Files 6-K on Share Transaction
Ticker: HLNCF · Form: 6-K · Filed: Aug 21, 2025 · CIK: 1900304
Sentiment: neutral
Topics: share-transaction, sec-filing, foreign-private-issuer
TL;DR
Haleon plc filed a 6-K on Aug 21, 2025, detailing a transaction in its own shares.
AI Summary
On August 21, 2025, Haleon plc announced a transaction involving its own shares. The company filed a Form 6-K report with the SEC, which is a report of a foreign private issuer. This filing includes Exhibit 99.1, detailing the "Transaction in Own Shares."
Why It Matters
This filing provides transparency to investors regarding Haleon's activities with its own stock, which can impact share count and valuation.
Risk Assessment
Risk Level: low — The filing is a routine report of a share transaction and does not indicate any immediate financial distress or significant operational changes.
Key Numbers
- 6-K — Form Type (Report of Foreign Private Issuer)
Key Players & Entities
- Haleon plc (company) — Registrant
- August 21, 2025 (date) — Filing date and transaction date
- 001-41411 (other) — SEC Commission File Number
- DRVW 2022 Ltd (company) — Former company name
FAQ
What type of transaction did Haleon plc engage in with its own shares?
Haleon plc engaged in a "Transaction in Own Shares" as detailed in Exhibit 99.1 of the Form 6-K filing.
When was this transaction in own shares reported?
The transaction was reported on August 21, 2025, as part of a Form 6-K filing.
What is the SEC filing number for Haleon plc?
Haleon plc's SEC Commission File Number is 001-41411.
What is the former name of Haleon plc?
The former name of Haleon plc was DRVW 2022 Ltd.
What is the primary purpose of a Form 6-K filing?
A Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the company has made or is required to make public in its home country.
Filing Stats: 575 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-08-21 06:21:33
Filing Documents
- a1572w.htm (6-K) — 32KB
- a1572w000.jpg (GRAPHIC) — 3KB
- 0001654954-25-009872.txt ( ) — 38KB
From the Filing
IN OWN SHARES a1572w UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of August 2025   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description          99.1 21 August 2025 - “Transaction in Own Shares”         99.1     Haleon plc:   Transaction in own shares   21 August 2025:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of 930,345 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation   under the second tranche of its share buyback programme announced on 31 July 2025.     London Stock Exchange CBOE (UK)/BXE CBOE (UK)/CXE Date of purchase: 20 August 2025 20 August 2025 20 August 2025 Number of Shares purchased: 930,345 - - Highest price paid per Share (p): 367.0000 - - Lowest price paid per Share (p): 360.9000 - - Volume weighted average price paid per Share (p): 363.4411 - -   Following the settlement of the above, the Company's registered share capital   is 8,970,871,750 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares.   Therefore, the number of ordinary shares with voting rights is 8,966,991,545 and   this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/1566W_1-2025-8-20.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media Jo Russell   +44 7787 392441 Zo ë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Victoria Durman +44 7894 505730 Email:   investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as  Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu  and  Voltaren  - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .      SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: August 21, 2025 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary